James Cardia

USPTO Granted Patents = 22 (Patent Applications = 6)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 16)

Average Co-Inventor Count = 6.2

ph-index = 13

Forward Citations = 569(Granted Patents)

Company Filing History:

12 out of 22

Phio Pharmaceuticals Corp.

patents

9 out of 16

Rxi Pharmaceuticals Corporation

patents

1 out of 1

Rxi Parmaceuticals Corporation

where one patent can have more than one assignee

Years Active: 2014-2023

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11584933 - RNA interference in ocular indications (2023-02-21),

2. 11279934 - Methods for treating cancer using nucleic acids targeting MDM2 or MYCN (2022-03-22),

3. 11118178 - Reduced size self-delivering RNAI compounds (2021-09-14),

4. 11021707 - Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA (2021-06-01),

5. 11001845 - Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) (2021-05-11),

6. 10913948 - RNA interference in dermal and fibrotic indications (2021-02-09),

7. 10876119 - Reduced size self-delivering RNAI compounds (2020-12-29),

8. 10815485 - RNA interference in skin indications (2020-10-27),

9. 10774330 - Reduced size self-delivering RNAI compounds (2020-09-15),

10. 10662430 - RNA interference in ocular indications (2020-05-26),

11. 10240149 - Reduced size self-delivering RNAi compounds (2019-03-26),

12. 10184124 - RNA interference in ocular indications (2019-01-22),

13. 10041073 - Reduced size self-delivering RNAi compounds (2018-08-07),

14. 9963702 - RNA interference in dermal and fibrotic indications (2018-05-08),

15. 9938530 - RNA interference in skin indications (2018-04-10),

Title: Innovations of James Cardia in Ocular and Cancer Treatment

Introduction

James Cardia is an esteemed inventor based in Franklin, Massachusetts, known for his significant contributions to the field of biomedicine. With a remarkable portfolio of 22 patents, Cardia has focused his research on RNA interference, particularly concerning ocular indications and cancer treatment. His innovative approaches have opened new avenues for therapeutic interventions.

Latest Patents

Among James Cardia's latest patents are two notable inventions. The first is related to RNA interference in ocular indications, focusing on the ocular administration of sd-rxRNA and rxRNAori molecules. This invention promises to enhance treatment approaches for eye-related conditions through advanced molecular techniques. The second patent involves methods for treating cancer using nucleic acids that target specific genes, namely the mouse double minute homologs (MDM1, MDM2, MDM3, MDM4) and the MYCN oncogene. This method presents a targeted strategy for cancer treatment by introducing therapeutic nucleic acid molecules to combat cancerous cells effectively.

Career Highlights

James Cardia has made a significant impact throughout his career, particularly through his roles at Phio Pharmaceuticals Corporation and Rxi Pharmaceuticals Corporation. His work at these companies has allowed him to translate his research into practical applications, contributing to the advancement of medicine through innovative treatment methodologies.

Collaborations

Collaboration has played a vital role in Cardia's career. He has worked alongside notable professionals such as Anastasia Khvorova and William Salomon. These partnerships have undoubtedly enriched his research and contributed to the success of his patented innovations.

Conclusion

James Cardia continues to be a leading figure in the biomedicine sector, with his inventions holding great promise for both ocular conditions and cancer treatment. His commitment to innovation exemplifies how dedicated researchers can lead to breakthroughs with the potential to change lives. Through his patents, Cardia's contributions will likely impact the medical field for years to come.

This text is generated by artificial intelligence and may not be accurate.